Advertisement
Organisation › Details
Arvelle Therapeutics GmbH
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. *
Start | 2019-02-14 established (approx) | |
Industry | CNS drug (neurological drug) | |
Industry 2 | cenobamate | |
Person | Altmeyer, Mark (Arvelle Therapeutics 201902– CEO before Axovant Sciences + BMS + Otsuka America Pharmaceutical) | |
Region | Zug ZG | |
Country | Switzerland | |
Street | 6 Zählerweg | |
City | 6300 Zug ZG | |
Address record changed: 2022-10-29 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Arvelle Therapeutics GmbH. (2/14/19). "Press Release: Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe". Basel. | ||
Record changed: 2024-01-20 |
Advertisement
More documents for Angelini (Group)
- [1] Angelini Ventures S.p.A.. (3/21/24). "Press Release: Angelini Ventures Invests into Extended €75.8 Million ($82 Mmillion) Series C Financing Round for Nouscom". Rome....
- [2] Arvelle Therapeutics GmbH. (1/4/21). "Press Release: Angelini Pharma Acquires Arvelle Therapeutics to Create a Leading European Innovator in Central Nervous System (CNS) and Mental Health Disorder Treatments". Rome....
- [3] Arvelle Therapeutics GmbH. (5/26/20). "Press Release: Arvelle Announces Closing of Final Tranche of Series A Financing Round". Zug....
- [4] Arvelle Therapeutics GmbH. (2/14/19). "Press Release: Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top